|
Endo Petitions FDA to Keep Opana Control as More ANDAs Are Submitted
Endo Pharmaceuticals is petitioning the FDA to require generics referencing its crush-resistant pain drug, Opana ER CRF, demonstrate they are similarly crush-resistant.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives